Elizabeth Buck
Vermogen: 314 855 $ op 30-06-2026
Vermogen: 314 855 $ op 30-06-2026
Elizabeth Buck is the founder of Black Diamond Therapeutics, Inc. since 2014, holding the title of Chief Scientific Officer.
Former job at OSI Pharmaceuticals, Inc. from 2005 to 2013 as Assistant Director-Advanced Preclinical.
Former job at MetaStat, Inc. from 2013 to 2014 as Chief Scientific Officer-Therapeutics.
Education includes an undergraduate degree from the University of New Hampshire and a doctorate from Icahn School of Medicine at Mount Sinai.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 21-01-2026 | 170.192 ( 0,3% ) | 314 855 $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Oprichter | 01-01-2014 |
| Bedrijven | Functie | Einde |
|---|---|---|
| METASTAT, INC. | Hoofd Techniek/Wetenschap/O&O | 01-12-2014 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
University of New Hampshire
University of New Hampshire Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MetaStat, Inc.
MetaStat, Inc. Electrical ProductsProducer Manufacturing Develops cancer diagnostics technologies | Producer Manufacturing |
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau